Sponsored Content
Novartis
Novartis Opens Second Biotech Facility in Austria
The pharmaceutical company Novartis has commissioned its second state-of-the-art cell culture facility for the production of monoclonal antibodies in Kundl (Kufstein district). The opening of the facility, which has been invested in with a total of €500 million, along with its sister facility in Schaftenau (Kufstein district), which opened in June 2024, is seen as a strong signal for the Austrian life sciences sector. With this expansion, Novartis is creating around 100 new jobs in Kundl and strengthening its global production capacity.
October 21, 2025
Swiss Novartis Opens Fastest Cell Culture Facility in Tyrol
Novartis opened a state-of-the-art cell culture facility for the production of monoclonal antibodies in Schaftenau, Tyrol.
June 24, 2024
Austrian Leadership Programs Begins With the Subject of “Life Science”
The Austrian Leadership Programs (ALPs) will run its 15th edition this year from April 17 to 21. Young leaders from around the world will gather in Vienna to discuss and represent the topic of “Life Science”
April 18, 2023
EU Commissioner Breton and Kurz Discuss Vaccine Production
In a meeting in Vienna, EU Commissioner Thierry Breton, who is responsible for vaccine production, Austria's Chancellor Sebastian Kurz and Minister for Economic Affairs Margarete Schramböck discussed the possibilities of Covid-19 vaccine production in the EU and talked about other issues evolving around the different Coronavirus vaccines.
March 9, 2021
Israel, Denmark and Austria Agree on Covid-19 Cooperation
Israel's Prime Minister Benjamin Netanyahu, Denmark's Prime Minister Mette Frederiksen and Austria's Chancellor Sebastian Kurz agreed on establishing a joint research and development foundation as well as on vaccine production. Chancellor Kurz stressed the importance of global cooperation in the fight against Covid-19.
March 5, 2021
Novartis Opens Production Facility for Innovative Eye Retina Product in Tyrol
The pharmaceutical company Novartis is investing EUR 27.4 million in the Kundl site in Tyrol to produce an active ingredient for a new therapy for wet age-related macular degeneration with 40 employees.
June 20, 2020
Intercell Looking for Private Equity Shareholder
According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.
September 27, 2011
Intercell Is Looking for Financial Investors
The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.
July 19, 2011
Fast News Search
